FBLG vs. WHWK, OCX, VIRI, CRBP, ADAG, ENTX, ORMP, JMAC, IVVD, and EXOZ
Should you be buying FibroBiologics stock or one of its competitors? The main competitors of FibroBiologics include Whitehawk Therapeutics (WHWK), OncoCyte (OCX), Virios Therapeutics (VIRI), Corbus Pharmaceuticals (CRBP), Adagene (ADAG), Entera Bio (ENTX), Oramed Pharmaceuticals (ORMP), Maxpro Capital Acquisition (JMAC), Invivyd (IVVD), and eXoZymes (EXOZ). These companies are all part of the "pharmaceutical products" industry.
FibroBiologics vs. Its Competitors
FibroBiologics (NASDAQ:FBLG) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.
FibroBiologics presently has a consensus target price of $13.00, suggesting a potential upside of 2,048.76%. Given FibroBiologics' stronger consensus rating and higher possible upside, analysts plainly believe FibroBiologics is more favorable than Whitehawk Therapeutics.
FibroBiologics has a beta of -0.78, suggesting that its stock price is 178% less volatile than the S&P 500. Comparatively, Whitehawk Therapeutics has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.
52.1% of Whitehawk Therapeutics shares are held by institutional investors. 20.8% of FibroBiologics shares are held by insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Whitehawk Therapeutics has a net margin of 99.42% compared to FibroBiologics' net margin of 0.00%. Whitehawk Therapeutics' return on equity of -56.73% beat FibroBiologics' return on equity.
In the previous week, FibroBiologics had 2 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 2 mentions for FibroBiologics and 0 mentions for Whitehawk Therapeutics. FibroBiologics' average media sentiment score of 0.00 equaled Whitehawk Therapeutics'average media sentiment score.
FibroBiologics has higher earnings, but lower revenue than Whitehawk Therapeutics. FibroBiologics is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Whitehawk Therapeutics beats FibroBiologics on 9 of the 15 factors compared between the two stocks.
Get FibroBiologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FBLG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FBLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
FibroBiologics Competitors List
Related Companies and Tools
This page (NASDAQ:FBLG) was last updated on 7/8/2025 by MarketBeat.com Staff
Free FBLG Stock Alerts